<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40890312</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Beta blockers linked to reduced 1-Year mortality in critically ill congestive heart failure patients with differential benefits across subgroups.</ArticleTitle><Pagination><StartPage>32263</StartPage><MedlinePgn>32263</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">32263</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-17483-3</ELocationID><Abstract><AbstractText>The efficacy of beta (&#x3b2;) blockers in critically ill patients with congestive heart failure (CHF) remains uncertain. This study investigated the association of &#x3b2; blockers use with 1-year all-cause mortality in these patients. Utilizing a retrospective cohort, the Medical Information Mart in Intensive Care-&#x2163; database, we identified critically ill CHF patients between 2008 and 2022. Stratified by &#x3b2; blockers use, Kaplan-Meier survival analysis and Cox models examined the association. Subgroup analyses investigated its effect across various patient characteristics. It comprised 13,908 eligible patients, of whom 74.3% received &#x3b2; blockers. &#x3b2; blockers use was associated with a reduction in mortality (HR: 0.51, 95% CI: 0.49-0.54, p&#x2009;&lt;&#x2009;0.001). Subgroup analyses revealed more benefits in non-elderly, male, hypertensive, diabetic or sepsis patients, as well as those undergoing mechanical ventilation or continuous renal replacement therapy (CRRT). Patients with elevated baseline heart rates or reduced left ventricular ejection fraction (LVEF) experienced greater benefits (p for interaction&#x2009;&lt;&#x2009;0.001). Additionally, selective &#x3b2;1 blockers offered superior survival benefits than non-selective &#x3b2; blockers in patients with LVEF of 50% or higher, and these benefits were pronounced in those with elevated baseline white blood cell counts (p for interaction&#x2009;=&#x2009;0.022). The use of &#x3b2; blockers was linked to a reduction of all-cause mortality in critically ill patients with CHF, particularly in subgroups characterized by younger age, male gender, hypertension, diabetes, sepsis, undergoing CRRT or mechanical ventilation, and those exhibiting elevated baseline heart rates or reduced LVEF. These findings are potentially influenced by unmeasured confounders and need to be confirmed by prospective randomized controlled trials.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9052-1691</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 401336, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yanming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. chenyanmingabcd0@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="Y">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Beta blockers</Keyword><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Congestive heart failure</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword></KeywordList><CoiStatement>Declarations. Consent for publication: Written informed consent for publication was obtained from all participants. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>2</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40890312</ArticleId><ArticleId IdType="pmc">PMC12402322</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-17483-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-17483-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roger, V. L. Epidemiology of heart failure: A contemporary perspective. <i>Circul. Res.</i><b>128</b>, 1421&#x2013;1434. 10.1161/circresaha.121.318172 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33983838</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Global trends in heart failure from 1990 to 2019: an age-period-cohort analysis from the global burden of disease study. <i>ESC Heart Fail.</i><b>11</b>, 3264&#x2013;3278. 10.1002/ehf2.14915 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11424301</ArticleId><ArticleId IdType="pubmed">38937863</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer, J. C. et al. Outcomes and predictors of mortality among cardiac intensive care unit patients with heart failure. <i>J. Card. Fail.</i><b>28</b>, 1088&#x2013;1099. 10.1016/j.cardfail.2022.02.015 (2022).
</Citation><ArticleIdList><ArticleId IdType="pubmed">35381356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual-Figal, D. A. et al. The Interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. <i>J. Am. Coll. Cardiol.</i><b>73</b>, 1016&#x2013;1025. 10.1016/j.jacc.2018.11.054 (2019).
</Citation><ArticleIdList><ArticleId IdType="pubmed">30846095</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashikuni, Y. et al. NLRP3 inflammasome activation through Heart-Brain interaction initiates cardiac inflammation and hypertrophy during pressure overload. <i>Circulation</i><b>147</b>, 338&#x2013;355. 10.1161/circulationaha.122.060860 (2023).
</Citation><ArticleIdList><ArticleId IdType="pubmed">36440584</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh, T. A. et al. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European journal of heart failure</i> 26, 5&#x2013;17 (2024). (2023). 10.1002/ejhf.3024</Citation><ArticleIdList><ArticleId IdType="pubmed">38169072</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite, M. et al. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis. <i>ESC Heart Fail.</i><b>10</b>, 1822&#x2013;1834. 10.1002/ehf2.14284 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10192281</ArticleId><ArticleId IdType="pubmed">36896801</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang, B., Zhang, R., Wu, X. &amp; Zhou, X. Optimal Pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: A Meta-analysis. <i>JAMA Netw. Open.</i><b>5</b>, e2231963. 10.1001/jamanetworkopen.2022.31963 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9490501</ArticleId><ArticleId IdType="pubmed">36125813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagat, A. A. et al. Continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. <i>JACC Heart Fail.</i><b>7</b>, 1&#x2013;12. 10.1016/j.jchf.2018.06.011 (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053043</ArticleId><ArticleId IdType="pubmed">30414818</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilstrap, L. G. et al. Initiation, continuation, or withdrawal of Angiotensin-Converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. <i>J. Am. Heart Association</i>. <b>6</b>, e004675. 10.1161/jaha.116.004675 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5523765</ArticleId><ArticleId IdType="pubmed">28189999</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman, D. N. et al. Association of &#x3b2;-Blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: A secondary analysis of the TOPCAT trial. <i>JAMA Netw. Open.</i><b>2</b>, e1916598. 10.1001/jamanetworkopen.2019.16598 (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902757</ArticleId><ArticleId IdType="pubmed">31800067</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, S. V. et al. Beta-Blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction. <i>JACC Heart Fail.</i><b>11</b>, 893&#x2013;900. 10.1016/j.jchf.2023.03.017 (2023).
</Citation><ArticleIdList><ArticleId IdType="pubmed">37140513</ArticleId></ArticleIdList></Reference><Reference><Citation>Palau, P. et al. Effect of &#x3b2;-Blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. <i>J. Am. Coll. Cardiol.</i><b>78</b>, 2042&#x2013;2056. 10.1016/j.jacc.2021.08.073 (2021).
</Citation><ArticleIdList><ArticleId IdType="pubmed">34794685</ArticleId></ArticleIdList></Reference><Reference><Citation>Peikert, A. et al. Contemporary use and implications of Beta-Blockers in patients with HFmrEF or hfpef: the DELIVER trial. <i>JACC Heart Fail.</i><b>12</b>, 631&#x2013;644. 10.1016/j.jchf.2023.09.007 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">37767674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddoura, R. et al. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis. <i>Curr. Probl. Cardiol.</i><b>49</b>, 102376. 10.1016/j.cpcardiol.2024.102376 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">38184132</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto, S. et al. Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. <i>Eur. Heart J.</i><b>27</b>, 124&#x2013;139. 10.1002/ejhf.3383 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">39215677</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veldhuisen, D. J. et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart Failure). <i>J. Am. Coll. Cardiol.</i><b>53</b>, 2150&#x2013;2158. 10.1016/j.jacc.2009.02.046 (2009).
</Citation><ArticleIdList><ArticleId IdType="pubmed">19497441</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdin, A. et al. Ivabradine improves win ratios of heart failure outcomes in patients with reduced ejection fraction - insights from the SHIFT trial. <i>Eur. J. Heart Fail.</i>10.1002/ejhf.3648 (2025).
</Citation><ArticleIdList><ArticleId IdType="pubmed">40159840</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y. et al. Blood pressure response index and clinical outcomes in patients with septic shock: a multicenter cohort study. <i>EBioMedicine</i><b>106</b>, 105257. 10.1016/j.ebiom.2024.105257 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11338059</ArticleId><ArticleId IdType="pubmed">39059317</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). <i>Jama</i><b>315</b>, 801&#x2013;810. 10.1001/jama.2016.0287 (2016).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansournia, M. A. &amp; Nazemipour, M. Recommendations for accurate reporting in medical research statistics. <i>Lancet</i><b>403</b>, 611&#x2013;612. 10.1016/s0140-6736(24)00139-9 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">38368003</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele, T. J. &amp; Ding, P. Sensitivity analysis in observational research: introducing the E-Value. <i>Ann. Intern. Med.</i><b>167</b>, 268&#x2013;274. 10.7326/m16-2607 (2017).
</Citation><ArticleIdList><ArticleId IdType="pubmed">28693043</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy, S. P., Kakkar, R., McCarthy, C. P. &amp; Januzzi, J. L. Jr. Inflammation in heart failure: JACC State-of-the-Art review. <i>J. Am. Coll. Cardiol.</i><b>75</b>, 1324&#x2013;1340. 10.1016/j.jacc.2020.01.014 (2020).
</Citation><ArticleIdList><ArticleId IdType="pubmed">32192660</ArticleId></ArticleIdList></Reference><Reference><Citation>Santas, E. et al. High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure. <i>Sci. Rep.</i><b>14</b>, 21672. 10.1038/s41598-024-72137-0 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11408489</ArticleId><ArticleId IdType="pubmed">39289385</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepe, M. S. &amp; Fleming, T. R. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. <i>Biometrics</i><b>45</b>, 497&#x2013;507 (1989).
</Citation><ArticleIdList><ArticleId IdType="pubmed">2765634</ArticleId></ArticleIdList></Reference><Reference><Citation>Eraky, A. M. et al. Beta-Blockers as an Immunologic and autonomic manipulator in critically ill patients: A review of the recent literature. <i>Int. J. Mol. Sci.</i><b>25</b>, 8058. 10.3390/ijms25158058 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11311757</ArticleId><ArticleId IdType="pubmed">39125627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cautela, J. et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. <i>Eur. J. Heart Fail.</i><b>22</b>, 1357&#x2013;1365. 10.1002/ejhf.1835 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540603</ArticleId><ArticleId IdType="pubmed">32353213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. Impact of &#x3b2;-blockers on in-hospital mortality in patients with heart failure: a retrospective propensity-score matched analysis based on MIMIC-IV database. <i>Front. Pharmacol.</i><b>15</b>, 1448015. 10.3389/fphar.2024.1448015 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11347275</ArticleId><ArticleId IdType="pubmed">39193346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Milla, J. et al. Beta-blocker therapy in elderly patients with renal dysfunction and heart failure. <i>J. Geriatric Cardiology: JGC</i>. <b>18</b>, 20&#x2013;29. 10.11909/j.issn.1671-5411.2021.01.005 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7868915</ArticleId><ArticleId IdType="pubmed">33613656</ArticleId></ArticleIdList></Reference><Reference><Citation>Deswal, A. Heart failure with reduced ejection fraction and renal dysfunction: Beta-Blockers do not disappoint. <i>J. Am. Coll. Cardiol.</i><b>74</b>, 2905&#x2013;2907. 10.1016/j.jacc.2019.10.012 (2019).
</Citation><ArticleIdList><ArticleId IdType="pubmed">31806134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordi, I. R. et al. Prognostic significance of changes in heart rate following Uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clin. Res. Cardiol.</i><b>108</b>, 797&#x2013;805. 10.1007/s00392-018-1409-x (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584244</ArticleId><ArticleId IdType="pubmed">30610382</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, J. J. et al. Myocardial strain for identification of &#x3b2;-Blocker responders in heart failure with preserved ejection fraction. <i>J. Am. Soc. Echocardiography: Official Publication Am. Soc. Echocardiography</i>. <b>32</b>, 1462&#x2013;1469e1468. 10.1016/j.echo.2019.06.017 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31540679</ArticleId></ArticleIdList></Reference><Reference><Citation>Seravalle, G. et al. Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. <i>J. Hypertens.</i><b>37</b>, 443&#x2013;448. 10.1097/hjh.0000000000001856 (2019).
</Citation><ArticleIdList><ArticleId IdType="pubmed">30020242</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, C. M. et al. Cardioselective Versus Nonselective &#x3b2;-Blockers After Myocardial Infarction in Adults With Chronic Obstructive Pulmonary Disease. <i>Mayo Clinic proceedings</i> 97, 531&#x2013;546 (2022). 10.1016/j.mayocp.2021.07.020</Citation><ArticleIdList><ArticleId IdType="pubmed">35135688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim, J. et al. Beta blockers are associated with lower all-cause mortality among HFpEF patients. <i>Clin. Res. Cardiol.</i><b>113</b>, 951&#x2013;958. 10.1007/s00392-024-02451-0 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">38695899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Y. et al. Decreased mortality with Beta-Blocker therapy in HFpEF patients associated with atrial fibrillation. <i>Cardiol. Res. Pract.</i><b>2020</b> (3059864). 10.1155/2020/3059864 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243006</ArticleId><ArticleId IdType="pubmed">32454997</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer, M. et al. Association between &#x3b2;-Blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry. <i>J. Card. Fail.</i><b>27</b>, 1165&#x2013;1174. 10.1016/j.cardfail.2021.04.015 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8573055</ArticleId><ArticleId IdType="pubmed">33971289</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon, S. D. et al. Angiotensin-Neprilysin Inhibition in heart failure with preserved ejection fraction. <i>N. Engl. J. Med.</i><b>381</b>, 1609&#x2013;1620. 10.1056/NEJMoa1908655 (2019).
</Citation><ArticleIdList><ArticleId IdType="pubmed">31475794</ArticleId></ArticleIdList></Reference><Reference><Citation>Reza, N. et al. Real-World experience and 36-Week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with Mavacamten. <i>JACC Heart Fail.</i><b>12</b>, 1123&#x2013;1125. 10.1016/j.jchf.2024.03.009 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156526</ArticleId><ArticleId IdType="pubmed">38661589</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah, S. J. et al. Cardiac myosin Inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. <i>JAMA Cardiol.</i><b>10</b>, 170&#x2013;175. 10.1001/jamacardio.2024.3810 (2025).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11822545</ArticleId><ArticleId IdType="pubmed">39347697</ArticleId></ArticleIdList></Reference><Reference><Citation>Badrov, M. B., Mak, S. &amp; Floras, J. S. Cardiovascular autonomic disturbances in heart failure with preserved ejection fraction. <i>Can. J. Cardiol.</i><b>37</b>, 609&#x2013;620. 10.1016/j.cjca.2020.12.006 (2021).
</Citation><ArticleIdList><ArticleId IdType="pubmed">33310140</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire, B. M., de Melo, F. M. &amp; Basso, A. S. Adrenergic signaling regulation of macrophage function: do we understand it yet? <i>Immunotherapy advances</i> 2, ltac010 (2022). 10.1093/immadv/ltac010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9585663</ArticleId><ArticleId IdType="pubmed">36284839</ArticleId></ArticleIdList></Reference><Reference><Citation>Girerd, N. et al. Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction. <i>Sci. Rep.</i><b>12</b>, 8574. 10.1038/s41598-022-12385-0 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9123183</ArticleId><ArticleId IdType="pubmed">35595781</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, H., Magaye, R., Kaye, D. M. &amp; Wang, B. H. Heart failure with preserved ejection fraction: the role of inflammation. <i>Eur. J. Pharmacol.</i><b>980</b>, 176858. 10.1016/j.ejphar.2024.176858 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">39074526</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoicescu, L., Cri&#x15f;an, D., Morgovan, C., Avram, L. &amp; Ghibu, S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. <i>Int. J. Mol. Sci.</i><b>25</b>, 794. 10.3390/ijms25020794 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10815792</ArticleId><ArticleId IdType="pubmed">38255869</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilis, P. et al. The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. <i>Int. Immunopharmacol.</i><b>111</b>, 109080. 10.1016/j.intimp.2022.109080 (2022).
</Citation><ArticleIdList><ArticleId IdType="pubmed">35908505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. <i>N. Engl. J. Med.</i><b>389</b>, 1069&#x2013;1084. 10.1056/NEJMoa2306963 (2023).
</Citation><ArticleIdList><ArticleId IdType="pubmed">37622681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosiborod, M. N. et al. Semaglutide in patients with Obesity-Related heart failure and type 2 diabetes. <i>N. Engl. J. Med.</i><b>390</b>, 1394&#x2013;1407. 10.1056/NEJMoa2313917 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">38587233</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlaug, B. A. et al. Effects of Tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. <i>Nat. Med.</i><b>31</b>, 544&#x2013;551. 10.1038/s41591-024-03374-z (2025).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11835708</ArticleId><ArticleId IdType="pubmed">39551891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>